Navigate HR+/HER2- metastatic breast cancer treatment by knowing which questions to ask your doctor about progression, next therapies, clinical trials, and quality of life.

Overall response rate (ORR) of 55% and median progression-free survival of 14.5 months in patients without TP53 gene mutationPhase 2 results ...

Dr Avan Armaghani discusses earlier use of ADCs, artificial intelligence for recurrence prediction, and new endocrine therapy ...

The new HER2DX central nervous system (CNS) progression score predicts risk of brain progression in advanced HER2+ breast cancer, addressing a major unmet need in identifying patients at the highest ...

An artificial intelligence (AI) model created by integrating clinical, molecular, and histopathological data significantly ...

Giredestrant significantly improved IDFS over SOC endocrine therapy, reducing the risk of invasive disease recurrence or ...

Trodelvy did not show statistically significant PFS improvement over chemotherapy in hormone-receptor-positive/HER2-negative breast cancer post-endocrine therapy. Investigator-assessed PFS showed a ...

Giredestrant significantly improved IDFS in ER-positive, HER2-negative early breast cancer, reducing recurrence or death risk by 30% compared to SOC endocrine therapy. Subgroup analyses showed ...

The investigational, oral selective estrogen receptor degrader (SERD) giredestrant given as an adjuvant therapy showed significant improvement in invasive disease-free survival (iDFS) compared with ...

One in eight women in the U.S. will be diagnosed with breast cancer in their lifetime. For many, the diagnosis doesn’t end there — up to 30 percent of early-stage breast cancer cases will later ...

This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Miller: Before we ...

Aromatase inhibitors demonstrated superior disease-free survival and time to distant recurrence compared to SERMs in HR+/HER2+ early breast cancer. The benefits of aromatase inhibitors were consistent ...